Peptide Regulation & FDA News

The FDA approved rusfertide (Mimrylo, from Protagonist Therapeutics and Takeda) for erythrocytosis in adults with polycythemia vera who haven't achieved adequate control on other treatments. The approval rests on the phase 3 VERIFY trial, where 76.9% of rusfertide patients needed no phlebotomy between weeks 20 and 32 versus 32.9% on placebo. Dosing is weekly subcutaneous injection starting at 19 mg. Rusfertide is a hepcidin mimetic — the connection to the iron-regulatory peptide named in the companion research review; this article itself focuses on clinical results, dosing, and safety warnings.

Medivir has received a Notice of Allowance from the US Patent and Trademark Office for a patent covering the combination of its peptide prodrug fostrox and lenvatinib for treating liver cancers. This approval strengthens the company's intellectual property position in the US market, extending potential market exclusivity for this combination therapy until at least 2041.

A federal advisory panel has narrowly voted to recommend easing FDA restrictions on the compounding of specific peptides, including BPC-157 and TB-500. This advice, which is not binding, contradicts FDA scientists who warn of insufficient safety and efficacy data. The decision aligns with the views of Health Secretary Robert F. Kennedy Jr. and could lead to increased availability of these substances through telehealth and compounding pharmacies.

The European Commission has approved Novo Nordisk's oral semaglutide 25 mg tablet (Wegovy pill) for weight management, marking the first oral GLP-1 receptor agonist available in the EU. The approval is for adults with obesity or overweight with comorbidities. Additionally, the EC approved a 7.2 mg single-dose pen injection. Novo Nordisk plans to launch the tablet in the EU in the second half of 2026.

CLINUVEL's afamelanotide implant, the world's first systemic photoprotective drug, has won approval in Canada for preventing phototoxic reactions in adults with erythropoietic protoporphyria (EPP) — a rare disorder where daylight causes severe pain and burns. Canada becomes the fourth major market for the 16 mg implant after Europe, the USA and Australia, where it has now been given more than 21,000 times.

FDA determined that vasopressin in 0.9% sodium chloride injection, 50 units/50 mL (1 unit/mL) in a single-dose ready-to-use container, was not withdrawn from sale for reasons of safety or effectiveness. The determination clears the way for FDA to approve abbreviated new drug applications (ANDAs) for generic versions of the premixed vasopressin product if all other legal and regulatory requirements are met. The notice was filed under Docket No. FDA-2026-P-0525 and opens a path to expanded generic supply of the premixed formulation used in vasodilatory shock.

The American College of Physicians has issued a new clinical guideline naming semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) as preferred first-line drug treatments for adults with obesity, used alongside lifestyle changes. The recommendations were published in Annals of Internal Medicine and ranked other options like phentermine-topiramate, liraglutide, and naltrexone-bupropion below these GLP-1-based therapies. The guideline emphasizes individualized decisions weighing benefits, harms, cost, and patient preferences, and is designated a 'living guideline' to be updated as evidence evolves.

The UK's MHRA has approved Wegovy pill (oral semaglutide 25 mg tablets) as the first daily GLP-1 weight-loss pill for obesity and overweight in adults, based on the OASIS 4 phase 3 trial. The once-daily tablet offers an alternative to weekly injections alongside diet and exercise. Semaglutide 25 mg achieved roughly 14% weight loss versus 2% with placebo after 64 weeks. Novo Nordisk expects availability via private prescription within weeks.

Sanofi has formally requested that the FDA remove its type 1 diabetes drug, teplizumab, from Commissioner Marty Makary's expedited review program. This request follows an unusual intervention by acting CDER director Tracy Beth Høeg, who reportedly overruled career staff scientists regarding the drug's approval. The agency subsequently missed its decision deadline, raising concerns about political interference in the scientific review process.

The FDA has approved icotrokinra, marketed as Icotyde, as the first oral peptide treatment for moderate to severe plaque psoriasis in adults and adolescents. Developed by Johnson & Johnson, the drug works by blocking the interleukin-23 (IL-23) receptor. This approval provides a new systemic option for patients aged 12 and older who weigh at least 40 kg, addressing a historical gap in oral therapies that balance efficacy with safety.

The FDA has approved the first oral pill version of Wegovy for weight management. The pill contains semaglutide, the same active ingredient found in the injectable form and other GLP-1 agonists. Experts believe this new daily pill formulation will improve patient adherence by eliminating the barrier of needle phobia and normalizing obesity treatment similar to hypertension management.

The FDA has approved an oral once-daily 25 mg semaglutide formulation, the Wegovy pill, as the first oral GLP-1 receptor agonist for weight management. It showed ~16.6% mean weight loss in the OASIS 4 trial, comparable to injectable Wegovy 2.4 mg. Novo Nordisk plans a US launch in early January 2026.

The FDA has approved an oral version of Novo Nordisk’s Wegovy for weight loss and cardiovascular risk reduction. Clinical trials showed the pill achieves similar efficacy to the injectable form, with patients losing approximately 14% of their body weight. This approval marks the first time a GLP-1 pill has been cleared for obesity, potentially increasing access for those averse to injections.

The FDA has officially reversed its decades-old stance on menopausal hormone therapy, announcing the removal of black box warnings regarding cardiovascular, dementia, and breast cancer risks. Commissioner Marty Makary stated that the agency now recognizes the treatments offer significant benefits for heart, brain, and bone health. This decision revises the labeling requirements for estrogen and progestogen products to reflect a more nuanced, evidence-based understanding of their safety profile.

Cidara Therapeutics has received U.S. FDA Breakthrough Therapy designation for CD388, a long-acting antiviral conjugate designed for the prevention of seasonal influenza A and B. This regulatory milestone is supported by Phase 2b data showing statistically significant prevention of flu in healthy adults and targets high-risk populations who respond poorly to vaccines. The company is accelerating the development of CD388, with a Phase 3 trial now underway ahead of schedule.

The FDA has issued over 50 warning letters to telehealth companies and medical spas regarding the marketing of compounded GLP-1 obesity drugs. The letters target providers for making false or misleading claims, specifically implying that these compounded versions are identical to FDA-approved branded medications. This action is part of a broader Department of Health and Human Services initiative to regulate direct-to-consumer drug advertising.

The FDA established a 'green list' import alert on September 5, 2025 to block GLP-1 active pharmaceutical ingredients from unverified foreign sources. Facilities inspected and found compliant will be listed, while all other GLP-1 APIs face detention without physical examination. The action targets the surge in illegal compounded semaglutide and tirzepatide, which the agency links to dosing errors and adverse events.

The FDA sent warning letters to five companies for selling unapproved GLP-1 peptide products, including semaglutide, tirzepatide, and retatrutide, in interstate commerce. One company, Veronvy, was cited for misbranded oral GLP-1 products falsely claiming FDA approval. The letters target peptide vendors Xcel Peptides, Swisschems, Summit Research, and Prime Peptides. This is part of ongoing FDA enforcement against unapproved GLP-1 sales amid high demand for these drugs.

The FDA approved a new indication for Wegovy (semaglutide), a GLP-1 receptor agonist, to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight. This makes it the first weight-loss medication approved for cardiovascular risk reduction. The decision was based on a trial of over 17,600 participants showing reduced major adverse cardiovascular events versus placebo.

The FDA has issued a reminder to compounders clarifying the conditions under which compounded drugs qualify for exemptions under sections 503A and 503B of the FD&C Act, as national GLP-1 supply stabilizes. The agency explains when a compounded product is considered an 'essentially a copy' of a commercially available drug, using semaglutide combined with vitamin B12 as an example. Compounded products matching a commercially available drug in API, strength, and route of administration do not qualify for exemptions unless a prescriber documents a significant clinical difference for an individual patient.

The FDA approved Wegovy (semaglutide 2.4 mg) for adults with noncirrhotic MASH with moderate to advanced liver fibrosis. Related reporting shows once-weekly semaglutide significantly improved steatohepatitis and fibrosis over 72 weeks. This marks a major expansion of GLP-1 therapy into liver disease treatment.

The FDA has approved Wegovy (semaglutide) for treating metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis. The approval was granted under the accelerated approval pathway based on surrogate endpoints from a phase 3 trial, with confirmatory data still required. This is a first-of-its-kind approval expanding semaglutide's label beyond obesity and cardiovascular risk reduction.

The FDA issued a warning letter to NuScience Peptides LLC for marketing unapproved injectable peptide drugs, including GLP-1/GLP-2/GLP-3 products and other peptides, on its website. The agency determined these products are unapproved new drugs under the FD&C Act. FDA warned that failure to correct the violations could lead to seizure or injunction.

FDA approved Yorvipath (palopegteriparatide) injection for subcutaneous use in adults with hypoparathyroidism — the first FDA-approved hormone replacement for adults with the rare disorder. The approval drew on an 82-patient, 26-week trial in which 69% of Yorvipath patients versus 5% of placebo patients maintained normal calcium without active vitamin D or high-dose calcium supplements. The application received orphan drug designation and priority review; the drug was not studied in acute post-surgical hypoparathyroidism.

Radius Health announced FDA approval of TYMLOS (abaloparatide) to increase bone density in men with osteoporosis at high risk for fracture, expanding the drug beyond its original April 2017 approval for postmenopausal women. The approval was based on the Phase 3 ATOM study (BA058-05-019), a 12-month randomized, double-blind trial in 228 men. Lumbar spine BMD rose 8.5% with abaloparatide versus 1.2% with placebo, a 7.3% difference (p<0.0001).

Takeda announced that FDA approved extending the GATTEX (teduglutide) indication to pediatric patients 1 year of age and older with short bowel syndrome who depend on parenteral support. The approval was supported by a 24-week pediatric study (NCT02682381) in 59 patients aged 1-17. In the study, 69% (18/26) of patients on GATTEX 0.05 mg/kg/day reduced parenteral-support volume by 20% or more, and 3 of 26 (12%) weaned off parenteral support entirely.

BioPharma Dive reports the FDA approved Scholar Rock's Isembyld (apitegromab), the first muscle-targeted treatment for spinal muscular atrophy. The drug blocks myostatin, a protein that limits muscle growth, and is cleared for patients 2 and older alongside existing SMN2-targeted therapies. It is the first SMA therapy aimed directly at muscle loss rather than the underlying genetic mechanism.

The official Drugs@FDA record for NDA 021332 documents SYMLIN (pramlintide acetate) approval on 03/16/2005 as a Type 1 new molecular entity, with all three marketed strengths (SymlinPen presentations) now listed as Discontinued. The record's supplement history traces the drug's regulatory life from 2005 approval through the 2019 final labeling supplement.

Fierce Pharma reports FDA approval of MYCAPSSA (oral octreotide) as the first oral therapy for acromegaly maintenance, following a 2016 complete response and a patient-advocacy-driven refile. The piece details launch pricing at $5,152 per 28-day course and Chiasma's switch to a subscription model.

The New Zealand Rugby Anti-Doping Judicial Committee decision records Customs-intercepted mail containing, among other items, Biotech peptides, CJC-1295 (ipamorelin) 5/5mg, 3 x vials — a single combination vial naming both peptides, which the committee lists as a prohibited non-specified substance. The source labels the vial CJC-1295 (ipamorelin) without further DAC qualification; it is attributed to the with-DAC compound because unqualified CJC-1295 denotes the DAC form. A recreational athlete received a two-year sanction (backdated to provisional suspension on 9 August 2023) for importing and using the prohibited substances.

FDA's Dallas district office inspected Revive Rx LLC (Houston, TX) between January 27 and February 7, 2025 and issued a Form 483 citing sterile-failure observations — products exposed to sub-ISO 5 air and microbial contamination (mold and spore-forming bacteria) in production areas. The 483's product list includes Hexarelin 6 mg per Vial for Injection among the drugs the compounding pharmacy produced, alongside sermorelin and tesamorelin. The document is inspectional observations, not a final agency determination.

FDA warned API supplier Darmerica, LLC (Davie, FL) after a March 2025 inspection found CGMP failures that render its drug APIs adulterated, plus misbranding violations including distribution of APIs ineligible for 503A compounding. The letter specifically cites the firm's drug listing for Hexarelin Acetate (NDC 71052-621), which reported an incorrect active peptide ingredient. It ties the misbranding to products distributed for compounding use.

UFC featherweight Chad Mendes, 31, tested positive for GHRP-6 (Growth Hormone-Releasing Hexapeptide) from an out-of-competition urine collection on May 17, 2016 and accepted a two-year sanction. USADA states the peptide is prohibited at all times under the UFC/WADA anti-doping rules (class S2, peptide hormones). His ineligibility began June 10, 2016, with results from May 17, 2016 onward disqualified.

FDA's running list of bulk drug substances that present significant safety risks in compounding names GHRP-2, GHRP-6, ipamorelin acetate, CJC-1295 and AOD-9604. GHRP-2 and GHRP-6 were added to the 503B risk list on September 29, 2023 over immunogenicity concerns, and FDA notes serious adverse events for CJC-1295 (increased heart rate, systemic vasodilatory reactions). The list confirms these peptides are treated by FDA as unsafe-for-compounding substances.

FDA warned Tailor Made Compounding LLC (Nicholasville, KY) after a 2018 inspection found it compounded drug products with bulk substances ineligible for 503A exemptions. The letter explicitly lists the compounded substances: Follistatin, GHRP-2, GHRP-6, AOD 9604, BPC 157, Bremelanotide (PT-141), Cerebrolysin, DSIP, Epitalon, GHK-Cu, Ipamorelin, LL-37, Melanotan II, Selank, Semax, and CJC 1295, among others. The firm was cited for insanitary aseptic processing (adulteration), unapproved new drugs, and misbranding, and removed GHRP-2 and GHRP-6 from its formulary in response.

The FDA has approved a 3-month injectable formulation of leuprolide mesylate (Camcevi 21 mg) for advanced prostate cancer, adding a less frequent dosing option to the workhorse GnRH-agonist class. Approval rested on the phase 3 FP-001 trial in 144 patients, which showed the formulation keeps testosterone suppressed to castrate levels in about 98% of men.

China's regulator has cleared mazdutide, the world's first dual glucagon/GLP-1 receptor agonist cleared anywhere for weight loss, for adults with overweight or obesity on top of diet and exercise. In the pivotal GLORY-1 trial the 6 mg dose produced 14.8% mean weight loss at 48 weeks, with half of participants losing at least 15% of body weight and liver fat falling by around 80%. The approval opens a new drug class beyond semaglutide and tirzepatide for the world's largest obesity market.

The FDA issued a warning letter to Peak Performance Peptides, an online seller, for marketing unapproved injectable peptide drugs including retatrutide, semaglutide, PT-141, tesamorelin, and SS-31 via its website. The agency stated these products are unapproved new drugs under the FD&C Act and warned of possible seizure or injunction if violations are not corrected. The letter highlights ongoing FDA scrutiny of grey-market peptide sellers.

The FDA issued a warning letter to TXP Innovations LLC (dba Tex Peptides) after reviewing its website in July 2026 and finding it marketed unapproved injectable peptide drugs, including semaglutide, tirzepatide, retatrutide, SS-31 (elamipretide), tesamorelin, and PT-141 (bremelanotide). The agency deemed these unapproved new drugs under section 505(a) of the FD&C Act. The letter warns that continued violations could trigger seizure or injunction. It underscores FDA's ongoing crackdown on unapproved peptide products sold directly to consumers online.

The FDA issued a warning letter to Peptide Partners LLC for marketing unapproved peptide drugs, including semaglutide, tirzepatide, retatrutide, elamipretide, tesamorelin, and PT-141, via its website. The agency stated these products violate the Federal Food, Drug, and Cosmetic Act as unapproved new drugs. The letter highlights the risks of injectable unapproved products and warns of potential seizure or injunction if violations persist.

The FDA has finalized a guidance document outlining its enforcement discretion policy for dietary supplements containing N-acetyl-L-cysteine (NAC). While the agency maintains that NAC is legally excluded from the dietary supplement definition because it was approved as a drug prior to being marketed as a supplement, it will not prioritize enforcement against compliant products. This policy allows lawfully marketed NAC products to remain on the market pending the completion of a future rulemaking process.

The FDA has approved a new subcutaneous formulation of the cancer immunotherapy nivolumab, co-formulated with the peptide enzyme hyaluronidase-nvhy, under the brand name Opdivo Qvantig. This approval allows for injection under the skin rather than intravenous infusion across all solid tumor indications for adults. Clinical trials confirmed that the subcutaneous method provides comparable drug exposure and safety to the traditional IV infusion.

The FDA has approved enlicitide, marketed as Lipfendra, as the first oral PCSK9 inhibitor for treating hypercholesterolemia. Unlike existing injectable therapies in this class, this new drug offers a once-daily tablet option to lower LDL cholesterol in adults who require additional reduction beyond diet and maximally tolerated statins. Clinical trials involving over 3,200 patients demonstrated the drug's efficacy and safety profile.

The FDA has announced the agenda for the July 2026 meeting of the Pharmacy Compounding Advisory Committee (PCAC). The committee will review specific bulk drug substances, including BPC-157 and KPV, for potential inclusion on the 503A Bulks List. This meeting represents a critical regulatory step toward determining the legal status of these peptides for pharmacy compounding.

The FDA has granted accelerated approval to Novo Nordisk’s Wegovy (semaglutide) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. This decision is based on Phase 3 data from the ESSENCE trial, where the drug significantly outperformed placebo in resolving liver inflammation and improving scarring. Wegovy is now the first GLP-1 receptor agonist approved for this liver condition.

The FDA has approved Novo Nordisk's once-weekly GLP-1 receptor agonist Ozempic (semaglutide) to improve glycemic control in adults with type 2 diabetes. Based on the SUSTAIN Phase 3a clinical trial program involving over 8,000 adults, the drug demonstrated superior A1c reductions compared to sitagliptin and exenatide extended-release, as well as significant weight loss as a secondary benefit. The drug will be available in 0.5 mg and 1 mg pre-filled pen doses.

An FDA advisory panel has voted to narrowly reject the compounding of tirzepatide while narrowly backing the compounding of semaglutide and another GLP-1 drug. This decision comes as the FDA faces political pressure from the Trump administration and Robert F. Kennedy Jr. to increase access to these weight-loss medications. The votes reflect a contentious debate between FDA staff warning about safety risks and peptide enthusiasts advocating for broader availability.

An FDA advisory panel has voted to allow compounding pharmacies to produce copies of certain popular peptide-based weight loss and diabetes drugs, specifically tirzepatide, semaglutide, and retatrutide, during periods of drug shortage. The panel rejected a proposal to allow compounding for a fourth peptide. This decision is a significant victory for the compounding industry and patients seeking lower-cost alternatives, but it raises safety concerns among FDA staff regarding the quality of non-FDA approved versions.

An FDA advisory panel has voted to allow the compounding of tirzepatide and semaglutide, major GLP-1 agonists used for weight loss and diabetes, while rejecting a petition for a third peptide. This decision is a significant victory for the compounding industry and patients seeking lower-cost alternatives to branded drugs like Mounjaro and Zepbound, though it bypasses standard safety approvals.

In December 2024 the FDA approved Eli Lilly's Zepbound (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity - the first prescription medicine ever cleared for the sleep disorder. The indication was supported by two randomized, placebo-controlled SURMOUNT-OSA trials showing reductions in apnea-hypopnea events and body weight. The approval expands the peptide-based GLP-1/GIP agonist franchise beyond diabetes (Mounjaro) and obesity (Zepbound) into a cardiometabolic comorbidity that affects tens of millions of Americans, and it positions tirzepatide as a disease-modifying therapy rather than a cosmetic weight-loss drug.

After a multi-year pharmacovigilance review triggered by a 2024 WHO VigiBase disproportionality signal, the FDA concluded that GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, and related drugs) do not increase the risk of suicidal ideation or behavior and formally requested manufacturers remove the related warning labeling. The finding aligns with a parallel European Medicines Agency (EMA) review that likewise found no causal link. Large 2025 cohort studies and meta-analyses published in BMJ and other journals consistently showed no elevated suicide risk versus comparator drugs. The episode illustrates how spontaneous-report databases can flag signals that controlled analyses later rule out.

Across 2025-2026 the FDA's Office of Compliance issued a string of warning letters to internet peptide retailers - including USApeptide.com (February 2025), Gram Peptides (March 2026), and Wholesale Peptide (June 2026) - alleging they are selling unapproved new drugs in violation of Section 505(a) of the FD&C Act. The letters single out products marketed for healing, recovery, and research that the agency says carry disease-treatment claims triggering drug status. Named substances include BPC-157, TB-500 (thymosin beta-4), CJC-1295, ipamorelin, and GHK-Cu. The enforcement runs in tension with the July 2026 PCAC vote recommending several of these same peptides for the 503A compounding list, but legally the two tracks are separate.

On February 21, 2025, the FDA determined that the national shortage of injectable semaglutide (Ozempic/Wegovy) was resolved and removed it from the drug-shortage list, triggering a phased wind-down of pharmacy compounding. State-licensed 503A compounding pharmacies generally lost their shortage-list exception by April 22, 2025, and FDA-registered 503B outsourcing facilities had until May 22, 2025 to cease production. The move mirrors the earlier resolution of the tirzepatide shortage and re-establishes that Novo Nordisk's branded products are the only FDA-approved semaglutide injectables. A pending court challenge left narrow enforcement discretion for some 503A operations, but the policy direction is settled: mass compounding of semaglutide is ending as branded supply catches up with demand.

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee recommended adding six of seven reviewed peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) to the Section 503A Bulks List and rejected Emideltide/DSIP. The vote is advisory only — not a final FDA decision and not legal authorization to compound. FDA must still complete formal notice-and-comment rulemaking (typically 12–24 months) before any change in legal status.